会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 22. 发明申请
    • PHARMACEUTICAL PREPARATION
    • 药物制剂
    • WO2009104939A3
    • 2009-11-19
    • PCT/KR2009000856
    • 2009-02-23
    • HANALL PHARMACEUTICAL CO LTDKIM SUNG WUKJUN SUNG SOOJO YOUNG GWANKOO JA SEONGSON JAW WOONKIM JIN WOOK
    • KIM SUNG WUKJUN SUNG SOOJO YOUNG GWANKOO JA SEONGSON JAW WOONKIM JIN WOOK
    • A61K9/52A61K9/00A61K9/22A61K31/165A61K31/41A61K47/00
    • A61K9/209A61K9/0004A61K31/165A61K31/41
    • Disclosed is a pharmaceutical preparation including a compartment containing a renin inhibitor as a pharmacologically active component, and a compartment containing HMG-CoA reductase inhibitor as a pharmacologically active component, wherein one of compartments is an advance release compartment and the other of the compartments is a retard release compartment. The combination preparation of the present invention delivers the renin inhibitor and HMG-CoA reductase inhibitor with a time difference at a specific speed, reducing undesirable side-effects, improving the potentiating effect and allowing for ease in teaching dosing regimens and enhanced patient compliance. Further, the pharmaceutical preparation of the present invention has pharmacological, clinical, scientific and economical advantages in the prevention or treatment of metabolic syndrome, cardiovascular disease, renal disease and the like as compared with the complex drug regimens in which medicament ingredients are taken individually or simultaneously.
    • 公开了一种药物制剂,其包含含有作为药理活性成分的肾素抑制剂的隔室和含有HMG-CoA还原酶抑制剂作为药理活性成分的隔室,其中一个隔室是提前释放隔室而另一个隔室是 缓释隔室。 本发明的组合制剂以特定的速度递送肾素抑制剂和HMG-CoA还原酶抑制剂,具有时间差异,减少不希望的副作用,改善增强作用,并且容易教示给药方案和增强患者依从性。 此外,本发明的药物制剂与单独服用药物成分的复合药物疗法相比在预防或治疗代谢综合征,心血管疾病,肾病等方面具有药理学,临床,科学和经济优势 同时。